CN110339247A - A kind of preparation and application of Wild jujube seeds extract - Google Patents
A kind of preparation and application of Wild jujube seeds extract Download PDFInfo
- Publication number
- CN110339247A CN110339247A CN201810297681.0A CN201810297681A CN110339247A CN 110339247 A CN110339247 A CN 110339247A CN 201810297681 A CN201810297681 A CN 201810297681A CN 110339247 A CN110339247 A CN 110339247A
- Authority
- CN
- China
- Prior art keywords
- ziziphi spinosae
- semen ziziphi
- preparation
- protein extract
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 240000008866 Ziziphus nummularia Species 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 34
- 210000000582 semen Anatomy 0.000 claims abstract description 29
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 4
- 238000009938 salting Methods 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 2
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000011534 incubation Methods 0.000 description 9
- 238000012549 training Methods 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 201000004810 Vascular dementia Diseases 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- -1 hydroxyl Propyl Chemical group 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- VGGSULWDCMWZPO-ODEMIOGVSA-N spinosin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=2C(=O)C=C(OC=2C=C1OC)C=1C=CC(O)=CC=1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VGGSULWDCMWZPO-ODEMIOGVSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PWVUXRBUUYZMKM-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCO PWVUXRBUUYZMKM-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 201000003695 Alexia Diseases 0.000 description 1
- 241000752021 Alexia Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 206010051078 Lacunar infarction Diseases 0.000 description 1
- 229910001051 Magnalium Inorganic materials 0.000 description 1
- RLAHWVDQYNDAGG-UHFFFAOYSA-N Methanetriol Chemical compound OC(O)O RLAHWVDQYNDAGG-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000037169 Retrograde Degeneration Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- VGGSULWDCMWZPO-UHFFFAOYSA-N flavoayamenin Natural products COC1=CC=2OC(C=3C=CC(O)=CC=3)=CC(=O)C=2C(O)=C1C1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O VGGSULWDCMWZPO-UHFFFAOYSA-N 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 150000005204 hydroxybenzenes Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- XSEOYPMPHHCUBN-FGYWBSQSSA-N hydroxylated lecithin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCC[C@@H](O)[C@H](O)CCCCCCCC XSEOYPMPHHCUBN-FGYWBSQSSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229950004422 hyetellose Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- XRRONFCBYFZWTM-UHFFFAOYSA-N octadecanoic acid;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCC(O)=O XRRONFCBYFZWTM-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001227 oxiracetam Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/006—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from vegetable materials
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/14—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to the preparation of Wild jujube seeds extract and application, the specific preparation method for designing semen ziziphi spinosae protein extract and its application in the drug or health care product of preparation prevention and treatment senile dementia.It is proved through experimental study, semen ziziphi spinosae protein extract can improve animal pattern memory disorders, improve its ability of learning and memory.
Description
Technical field
The invention belongs to pharmaceutical technology field, it is related to a kind of Wild jujube seeds extract in preparation and prevents and treats senile dementia
Drug or health care product in application.
Background technique
Senile dementia is a kind of central nervous system primary retrograde degeneration's disease, and onset is slow, the course of disease be it is chronic into
Row, it is 5~10 years average, characterized by comprehensive progressive dementia.It is mainly shown as memory, language, judgement, understanding, thinking, row
For higher nervous activities obstacles such as, personality and emotions, with aphasia, appraxia, agnosia, logagraphia and alexia etc..Senile dementia is main
Alzheimer dementia, cerebrovascular property senile dementia, mixed type and other types can be divided into.Wherein with Alzheimer (AD) and
Vascular dementia (VD) is the most common.
Alzheimer disease (Alzheimer ' s disease, AD) is a kind of maincenter mind based on progressive dementia
Degenerative disease through system.Its Clinical symptoms is memory and other cognition dysfunctions, and early clinic symptom includes movement, sense
Feel or coordination function defect.The main pathological change of AD patient is that extracellular amyloid albumen precipitation forms senile plaque, nerve
The missing of first fibre matting and extensive neuronal synapse, inflammation, oxidation are even downright bad.
Using dementia as the disease of main clinic symptoms due to caused by cerebrovascular disorder, just referred to as vascular dementia
(Vascluardementia, VD).From the perspective of neuropathology, VD includes ischemic and hemorrhagic cerebrovascular disease and the heart
It is dirty stop fighting cause cerebral hypoxia ischemia to damage caused by it is dull-witted.Wherein infarct dementia (MID) is most commonly seen, is cerebrovascular disease
Caused by caused intracerebral majority is dispersed in infraction or lacunar infarction stove.
With the development of society and the aging of population, senile dementia disease incidence increases with the growth at age.65 years old
In above old man, the disease incidence of Alzheimer disease is 5%-10%, in 85 years old or more old man, the hair of Alzheimer disease
Sick rate is up to 47%-50%.The research and development of senile dementia drug has become the hot spot of chemist and drug scholar concern.
Senile dementia pathogenesis is complicated, the drug that can not treat at all still both at home and abroad at present, therefore early treatment
It is most important.The therapeutic agent that has listed is broadly divided into two kinds at present, and one kind is anticholinesterase, as hydrochloric acid mostly how piperazine
Together, galanthamine, rivastigmine, huperzine are first-class；Another kind is excitatory amino acid receptor antagonists, such as hydrochloric acid beauty
Buddha's warrior attendant.Said medicine can improve the symptom of patients with Alzheimer disease in short term, but cannot alleviate the development of disease, and easily be formed resistance to
Medicine, adverse reaction are obvious；And traditional Chinese medicine has preferable clinical effectiveness in prevention and treatment mild cognitive impairment and senile dementia, has more
The integrally-regulated feature of approach, too many levels, and it is small using the toxic side effect of natural drug.Therefore, traditional Chinese medicine monomer or its effective group
The prevention and treatment that the extraction divided is applied to senile dementia has a very important significance.
Semen ziziphi spinosae is the dry mature seed of rhamnaceae plant wild jujube, and sweet in flavor and neutral in nature, return heart, spleen, liver, gallbladder channel have and support
The effect of liver, calming heart, tranquilizing the mind, arrest sweating is the common heart-nourishing tranquilizer of traditional Chinese medicine in treating insomnia.Semen ziziphi spinosae mainly contain three mushroom classes,
The bioactive ingredients such as flavonoids, fat oil.Modern pharmacology research shows that semen ziziphi spinosae has calmness in central nervous system
Hypnosis, anticonvulsion, antianxiety, antidepressant effect；There is anti-arrhythmia in cardiovascular system, improve myocardial ischemia, drop
The effect of blood lipid, blood pressure lowering；Simultaneously it has also been found that it is improved the effects of immunity is antitumor.Only has semen ziziphi spinosae ingredient saponin(e at present
A and spinosin are used to treat the document report of senile dementia, have no senile to preventing and treating about semen ziziphi spinosae protein extract
Dull-witted report.
Summary of the invention
The present invention extracts processing in view of the deficiencies of the prior art, to semen ziziphi spinosae, is with the protein extract of semen ziziphi spinosae
Proper auxiliary materials are added in main medicinal component, are used to prepare the drug or health food for preventing and treating Alzheimer's disease.
Semen ziziphi spinosae protein extract of the present invention is prepared according to preparation process below, processing step
It is:
(1) it by semen ziziphi spinosae medicinal material, cleans, dry, squeezing is deoiled；
(2) water or salting liquid is added in the dregs of a decoction after squeezing, is extracted 1-2 hours at 40-65 DEG C, filtered；
(3) merging filtrate, stand, centrifugation to get.
Wherein, salting liquid is sodium chloride solution or PBS buffer solution in step (2), and preferably concentration of salt solution is 0.05-
0.15mol/L；Extraction time described in step (2) can be 1 ~ 3 time.
Further study show that model mice space exploration ability can be improved in above-mentioned semen ziziphi spinosae protein extract, have
The effect for improving inflammatory model ability of learning and memory in mice is significant to prevention and treatment senile dementia.
Above-mentioned semen ziziphi spinosae protein extract contained by preparation per unit of the invention is 10mg~1000mg, can be given on demand
Medicine.Doctor can according to clinical needs, patient receiving treatment weight, to want frequency, to wanting approach and the course for the treatment of and patient
Individual difference adjust dosage, flexibly change.
Pharmaceutical preparation used in the present invention can in accordance with known methods, with one or more pharmaceutical carriers or dilution
Oral administration preparation is prepared in agent etc. together.
The solid pharmaceutical preparation of oral administration can be tablet, hard capsule, soft capsule, dripping pill, granule, powder,
Pill etc..It can be prepared according to their customary preparation methods, auxiliary material that can be medicinal is used during preparation.Example
Such as, filler (such as starch, dextrin, sucrose, lactose, calcium sulfate, carbon can be used in the preparation process of tablet or capsule
Sour calcium, micro- smart cellulose etc.), binder (such as methylcellulose, ethyl cellulose, polyvinylpyrrolidone, carboxymethyl starch
Sodium, gelatin, cornstarch etc.), disintegrating agent is (such as dry starch, crosslinked carboxymethyl fecula sodium, sodium carboxymethyl starch, low substitution hydroxyl
Propyl cellulose etc.), lubricant (such as magnesium stearate, stearic acid, superfine silica gel powder, polyethylene glycol, talcum powder).Tablet can be with
According to the method coating being currently known.Granule also needs to select corresponding corrigent (such as sucrose, syrupus citri).Soft capsule
Diluent used in the preparation of agent includes but is not limited to vegetable oil, mineral oil, propylene glycol, tween, polyethylene glycol (PEG) (200
One or more of~8000).Suspending agent include but is not limited to cellulose family for example sodium cellulose glycolate, hyetellose,
Ethyl cellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropyl methyl cellulose etc.；Gum class is such as
Arabic gum etc.；Other one or more of such as carbomers, polyvinyl alcohol.Emulsifier includes but is not limited to stearic acid
Sodium, enuatrol, spans (20~80), Tweens (20~80), glycerin monostearate, hydroxylated lecithin, diacetyl list are sweet
One or more of grease, diethylene glycol stearate, orthoformic acid, ethylene glycol monostearate, beeswax.Anti-corrosion used
Agent includes but is not limited to sorbic acid methyl esters, benzoic acid, sorbic acid, methyl p-hydroxybenzoate, nepal Gold methyl ester, Nepal's gold
One or more of ethyl ester, benzyl alcohol.In the preparation of pill, matrix includes but is not limited to polyethylene glycol (PEG) 6000, gathers
Ethylene glycol (PEG) 4000, polyethylene glycol (PEG) 1000, polyethylene glycol (PEG) 1500, odium stearate, glycerin gelatine, stearic acid,
Poloxamer etc.；Condensate liquid includes but is not limited to dimethicone, atoleine, vegetable oil etc..
Oral liquid can be mixture (oral solution), syrup, emulsion, suspension, elixir or suspension, can be with
It is to reconstitute the dry products taken with water or other suitable carriers before its use.These liquid preparations can be according to itself
Known method preparation, can be used medical additive during preparation, such as suspending agent (such as cellulose derivative, grape
Sugar/sucrose syrup, sorbitol syrups etc.), emulsifier (such as Arabic gum, soybean lecithin, lecithin, gelatin, Tweens), help
Suspension (such as glycerol, simple syrup, aluminum monostearate vegetable oil, colloid sulfuric acid magnalium), preservative (such as benzoic acid, hydroxy benzenes first
Sour methyl esters, nipasol, sorbic acid etc.).Flavor ameliorating substances, fragrant ingredient, sweetener etc. can also be added as needed.
It can be also used for preparing food supplement and/or guarantor by semen ziziphi spinosae protein extract prepared by the method for the present invention
Health food can be prepared into various dosage forms, such as tablet, capsule, oral solution, health drink, health protection tea of health food etc.；
It can also be used as food additives, be applied to food (such as bread, noodles), health protection tea, health drink etc..
Specific embodiment
The invention is further described below by specific embodiment.
A kind of embodiment 1: preparation process of semen ziziphi spinosae protein extract
Semen ziziphi spinosae raw medicinal herbs 1kg is weighed, is squeezed with oil press, the dregs of a decoction about 750g is obtained；2L 0.1mol/L PBS buffering is added in the dregs of a decoction
Liquid, 50 DEG C of water-baths are extracted 2 hours, and 200 mesh filter-cloth filterings remove slag；It is small that filter residue adds the 50 DEG C of water-baths extractions 2 of 2L PBS buffer solution
When；Merge secondary filtrate, 0-5 DEG C stands 2 hours；4000r/min, be centrifuged 30min, collect solid to get.
Embodiment 2: zoopery is carried out with extract (hereinafter referred to as P) prepared by embodiment 1, it was demonstrated that semen ziziphi spinosae protein extract
AlCl is combined to galactolipin3Dementia mice caused by model has therapeutic effect
1.1 animal
ICR mouse, SPF grades (credit number: SCXK (Soviet Union) 2017-0001), male, 20 ~ 30g, 100
1.2 medicine ordinances and medication
D-gal: physiological saline solution AlCl3: stoste normal saline dilution.
Drug: add physiological saline, 60 DEG C of ultrasound 2h, 4 DEG C of preservations after dissolution.
Modeling dosage D-gal:i.p 120mg/kg/d；AlCl3: i.g 30mg/kg/d
Drug dose P low dosage: 50mg/ml, P middle dosage: 100mg/ml, P high dose: 200mg/ml
Positive drug Doneppezil Hydrochloride: i.g 1.3mg/kg/d；Oxiracetam:: i.g 200mg/kg/d
Administered volume: 0.1ml/10g mouse
1.3 modeling method
It is grouped according to weight Stochastic Equilibrium, 6 groups in total: (1) blank control group (2) model group (3) P low dose group (4) P middle dosage
Group (5) P high dose group (6) Doneppezil Hydrochloride combines Oxiracetam group.Every morning, model group, each medicine group, positive drug group
Mouse peritoneal injects D-gal stomach-filling AlCl simultaneously3, negative control group stomach-filling physiological saline, continuous modeling 30d；When 31d, on
Noon gives D-gal+AlCl3, afternoon each medicine group gastric infusion, successive administration 30d.
1.4 Testing index and method
Morris water maze laboratory is carried out after modeling 30 days, ability of learning and memory changes situation after investigating the modeling of mouse inflammation；It makes
Morris water maze laboratory is carried out after mould 60 days again, investigates drug to ability of learning and memory improvement result caused by inflammatory model.
Gate position: mouse platform is placed in third quadrant
Statistical method: using statistic software SPSS 17.0, carries out one-way ANOVA analysis.
1.5 result
1. incubation period data are shown during training after mouse modeling 30 days:
During training, compared with blank group, each modeling group has significant difference, and incubation period significantly extends；Illustrate modeling success
(see Table 1).
Incubation period (s) during training after 1 mouse modeling of table 30 days
| Group | N | 1d | 2d | 3d | 4d | 5d |
| Control | 15 | 48.63±8.19 | 44.00±7.00 | 51.00±0.00 | 46.81±4.19 | 37.94±7.06 |
| Model | 19 | 61.00±0.00### | 58.21±2.79## | 58.25±2.75# | 54.98±3.29# | 53.83±3.77## |
| P is low | 15 | 58.67±2.33## | 56.67±4.33## | 59.50±1.50# | 53.68±5.20# | 50.15±5.26## |
| In P | 15 | 61.00±0.00## | 59.42±1.58### | 56.33±4.67 | 55.76±5.01## | 59.03±1.97### |
| P high | 15 | 61.00±0.00## | 61.00±0.00### | 61.00±0.00## | 55.92±5.08## | 59.29±1.71### |
| Positive drug | 15 | 58.36±2.64## | 58.36±2.64## | 55.68±3.92 | 56.74±4.26## | 57.51±3.49### |
Note: compared with blank group, #P < 0.05, ##P < 0.01, ###P < 0.001
2. model mice administration after training during incubation period as the result is shown:
During training, P high dose group mouse incubation period is most short, behaves oneself best, and is secondly P low dose group, illustrates that drug P has and changes
The effect of kind inflammatory model ability of learning and memory in mice.
2 galactolipin model mice water maze laboratory incubation period (s) of table
| Group | N | 1d | 2d | 3d | 4d |
| Control | 15 | 43.13±13.00 | 56.56±13.47 | 53.52±10.82 | 46.59±12.07 |
| Model | 19 | 55.99±11.40 | 47.06±11.29 | 52.31±11.77 | 56.32±10.85 |
| P is low | 15 | 37.13±13.21* | 35.50±12.03#* | 57.43±14.62 | 28.73±11.18##*** |
| In P | 15 | 42.26±14.60 | 52.34±14.37 | 69.39±13.45 | 38.81±9.09#** |
| P high | 15 | 22.02±10.72##*** | 40.15±13.13#* | 31.69±13.10##** | 21.28±9.46###*** |
| Positive drug | 15 | 56.19±16.58 | 47.59±14.77 | 64.54±14.46 | 47.47±18.52 |
Note: compared with blank group, #P < 0.05, ##P < 0.01, ###P < 0.001, compared with model group, * P < 0.05, * * P <
0.01, * P < 0.001 * *
3. mouse training during target quadrant distance ratio as the result is shown:
During training, compared with model group, P high dose group mouse target quadrant distance ratio is dramatically increased, and is secondly P low dose group
Mouse illustrates that model mice space exploration ability can be improved in drug P.
3 galactolipin model mice water maze laboratory target quadrant distance (%) of table
| Group | N | 1d | 2d | 3d | 4d |
| Control | 15 | 35.45±5.67 | 37.15±3.83 | 34.58±4.75 | 33.56±5.27 |
| Model | 19 | 38.87±3.53 | 39.04±4.02 | 35.10±3.20 | 32.88±5.76 |
| P is low | 15 | 38.91±4.53 | 51.60±6.50#* | 34.61±4.96 | 39.40±4.06 |
| In P | 15 | 33.99±5.76 | 29.53±4.87 | 29.20±4.07 | 39.77±5.06 |
| P high | 15 | 54.11±4.33#* | 49.34±3.78#* | 47.07±7.42#* | 50.70±6.96# ** |
| Positive drug | 15 | 38.28±3.98 | 40.57±5.95 | 39.52±5.69 | 42.06±6.85 |
Note: compared with model group, P < 0.05 * P < 0.05, * *；Compared with blank group, #P < 0.05
4. mouse training during target quadrant time ratio as the result is shown:
During training, compared with model group, P high dose group mouse target quadrant time ratio is dramatically increased, and is secondly P low dose group
Mouse illustrates that model mice space exploration ability can be improved in drug P.
4 galactolipin model mice water maze laboratory target quadrant time (%) of table
| Group | N | 1d | 2d | 3d | 4d |
| Control | 15 | 43.25±5.88 | 43.10±5.00 | 41.10±5.47 | 40.05±5.74 |
| Model | 19 | 44.16±3.96 | 46.69±4.78 | 39.64±3.69 | 44.06±6.27 |
| P is low | 15 | 44.98±5.90 | 56.43±6.71#* | 40.85±7.05 | 59.73±5.67#* |
| In P | 15 | 40.99±6.63 | 35.09±6.00 | 33.50±4.97 | 44.80±5.75 |
| P high | 15 | 64.07±4.24#* | 56.03±2.39#* | 54.18±7.53*# | 62.42±8.36#* |
| Positive drug | 15 | 45.25±4.66 | 45.43±5.16 | 42.47±5.80 | 50.34±8.20 |
Note: compared with model group, P < 0.05 *；Compared with blank group, #P < 0.05
5. Mice water maze testing result is shown:
Incubation period, P high dose group and P low dose group mouse incubation period substantially reduced the results show that compared with model group；
Target quadrant distance ratio is the results show that compared with model group, P high dose group and P middle dose group mouse target quadrant distance
Than dramatically increasing；
Target quadrant time ratio is the results show that compared with model group, P high dose group and P middle dose group mouse target quadrant time
Increase than display；
The results show that compared with model group, P high dose group mouse platform traversing times dramatically increase platform traversing times；Explanation
Model mice space exploration ability can be improved in drug P, has the function of improving inflammatory model ability of learning and memory in mice.
5 Mice water maze detection data of table
| Group | Incubation period (s) | Target quadrant distance (%) | Target quadrant time (%) | Platform traversing times |
| Control | 81.00±5.22 | 38.04±3.33 | 41.31±3.70 | 4.42±0.86 |
| Model | 104.00±8.09 | 38.07±3.50 | 40.55±3.92 | 2.87±0.55 |
| P is low | 88.00±7.14* | 37.09±2.90 | 39.28±2.76 | 2.91±0.62 |
| In P | 93.00±6.50 | 46.28±3.35* | 48.22±3.73* | 2.82±0.55 |
| P high | 80.00±6.87** | 48.58±4.41* | 50.12±4.43* | 5.25±0.88* |
| Positive drug | 97.74±13.26 | 36.12±2.80 | 38.75±2.88 | 3.56±0.50 |
Note: compared with model group, P < 0.01 * P < 0.05, * *
Embodiment 3: the preparation of semen ziziphi spinosae protein extraction composite capsule
The addition auxiliary material of semen ziziphi spinosae protein extract prepared by above-described embodiment 1 is crossed 80 meshes uniformly to mix, wet granulation, drum
Air-dry it is dry, with 20 mesh sieves, filling capsule, polishing package sterilization.
Its main component proportion is following (1000):
Semen ziziphi spinosae protein extract 100g
Microcrystalline cellulose 130g
Medical starch 100g
Embodiment 4: the preparation of semen ziziphi spinosae protein extract piece
The addition auxiliary material of semen ziziphi spinosae protein extract prepared by above-described embodiment 1 is crossed 80 meshes to be uniformly mixed, wet granulation, drum
It air-dries dry, with 20 mesh sieves, is added magnesium stearate, tabletting sterilizes after packaging.
The weight proportion of main component is (1000):
Semen ziziphi spinosae protein extract 100g
Medical starch 120g
Sodium carboxymethyl starch 10g
Microcrystalline cellulose 100g
Magnesium stearate 4g.
Claims (5)
1. a kind of semen ziziphi spinosae protein extract, it is characterised in that the extract is to be prepared as follows:
(1) it by semen ziziphi spinosae medicinal material, cleans, dry, squeezing is deoiled；
(2) water or salting liquid is added in the dregs of a decoction after squeezing, is extracted 1-2 hours at 40-65 DEG C, filtered；
(3) merging filtrate, stand, centrifugation to get.
2. the preparation method of semen ziziphi spinosae protein extract according to claim 1, it is characterised in that salting liquid in step (2)
For sodium chloride solution or PBS buffer solution, preferably concentration of salt solution is 0.05-0.15mol/L.
3. a kind of drug for preventing and treating senile dementia in preparation containing semen ziziphi spinosae protein extract described in claim 1
Or the application in health care product.
4. the purposes of semen ziziphi spinosae protein extract according to claim 3, it is characterised in that be mainly used for treating A Erci
The drug of the silent disease in sea or the application in health care product.
5. the application of semen ziziphi spinosae protein extract according to claim 4, it is characterised in that be made into various peroral dosage forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810297681.0A CN110339247A (en) | 2018-04-04 | 2018-04-04 | A kind of preparation and application of Wild jujube seeds extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810297681.0A CN110339247A (en) | 2018-04-04 | 2018-04-04 | A kind of preparation and application of Wild jujube seeds extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110339247A true CN110339247A (en) | 2019-10-18 |
Family
ID=68173665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810297681.0A Pending CN110339247A (en) | 2018-04-04 | 2018-04-04 | A kind of preparation and application of Wild jujube seeds extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110339247A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112353808A (en) * | 2020-11-18 | 2021-02-12 | 山西大学 | Application of spinosin in preparing medicine for relieving inflammation and inhibiting Alzheimer's disease |
| CN116236494A (en) * | 2023-02-21 | 2023-06-09 | 徐州医科大学 | Application of jujube jujube saponin A in the preparation of drugs for preventing or delaying cognitive dysfunction in diabetes |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101003829A (en) * | 2007-01-18 | 2007-07-25 | 石家庄旭尔美生物制品厂 | Polypeptide of seed of spine date, preparation method, and application |
| CN103113460A (en) * | 2013-03-05 | 2013-05-22 | 刘睿 | Extraction process for fructus cannabis globulin |
| CN103947817A (en) * | 2014-04-29 | 2014-07-30 | 广西壮族自治区粮油科学研究所 | Method for preparing semen cannabis protein powder from degreased semen cannabis residue |
-
2018
- 2018-04-04 CN CN201810297681.0A patent/CN110339247A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101003829A (en) * | 2007-01-18 | 2007-07-25 | 石家庄旭尔美生物制品厂 | Polypeptide of seed of spine date, preparation method, and application |
| CN103113460A (en) * | 2013-03-05 | 2013-05-22 | 刘睿 | Extraction process for fructus cannabis globulin |
| CN103947817A (en) * | 2014-04-29 | 2014-07-30 | 广西壮族自治区粮油科学研究所 | Method for preparing semen cannabis protein powder from degreased semen cannabis residue |
Non-Patent Citations (7)
| Title |
|---|
| 俄红梅: "《家庭常见病食疗与宜忌早知道》", 31 May 2016, 新疆人民卫生出版社 * |
| 刘静 等: "酸枣仁氨基酸组成分析及营养评价", 《食品研究与开发》 * |
| 张雪 等: "酸枣仁的化学成分和药理作用研究进展", 《食品工业科技》 * |
| 李斌 等: "《食品酶学与酶工程》", 30 September 2017, 中国农业大学出版社 * |
| 王沛: "《制药工艺学》", 31 August 2017, 中国中医药出版社 * |
| 王秀娟 等: "酸枣仁蛋白提取工艺的研究", 《粮油加工》 * |
| 赵节昌: "响应面法优化酸枣仁蛋白提取工艺", 《食品科学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112353808A (en) * | 2020-11-18 | 2021-02-12 | 山西大学 | Application of spinosin in preparing medicine for relieving inflammation and inhibiting Alzheimer's disease |
| CN116236494A (en) * | 2023-02-21 | 2023-06-09 | 徐州医科大学 | Application of jujube jujube saponin A in the preparation of drugs for preventing or delaying cognitive dysfunction in diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69836735T2 (en) | TREATMENT OF DARM CONSTIPATION | |
| CA2709958C (en) | Use of an extract made of leaves of ginkgo biloba | |
| CA2807283C (en) | Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease | |
| JP2023538664A (en) | Compositions of ginsenoside Rg3 and ginsenoside Rg5 and their pharmaceutical uses, including antitumor effects | |
| CN110339247A (en) | A kind of preparation and application of Wild jujube seeds extract | |
| CN102716459A (en) | Chinese medicinal composition for treating senile mild cognitive impairment and preparation method thereof | |
| CN104800608B (en) | A kind of herbal composite and its application with blood pressure reduction effect | |
| CN104027428B (en) | Preparation method of traditional Chinese medicine compound and application of traditional Chinese medicine compound in prevention and treatment of senile dementia | |
| CN110101744A (en) | A kind of pharmaceutical formulation of depression and preparation method thereof | |
| CN104138376A (en) | A sustained release agent improving anoxia endurance | |
| JPH0680577A (en) | Antitussive | |
| CN103028109B (en) | Traditional Chinese medicine agent for treating Alzheimer disease | |
| EP1796702B1 (en) | Use of lavender oil for the prophylaxis and treatment of somatization disorders and posttraumatic stress disorder | |
| CN107281207A (en) | Astragaloside I is preparing the purposes in preventing and treating the medicine or health products of senile dementia | |
| CN100370973C (en) | Traditional Chinese medicinal prepn. for treating obstruction of qi in the chest | |
| CN109394977B (en) | A kind of traditional Chinese medicine composition with blood lipid lowering function and preparation method and application thereof | |
| CN107050005A (en) | A kind of pharmaceutical composition for treating atherosclerosis and its application | |
| CN101461803B (en) | Use of grape inner ester | |
| CN112220870A (en) | A pharmaceutical composition for treating Alzheimer's disease | |
| CN107281203A (en) | Application of the Horse chest Nut P.E in preventing and treating medicine for senile dementia is prepared | |
| CN114404547B (en) | A prescription of Fuzheng Huayu ointment and its application | |
| CN114272300B (en) | Pharmaceutical composition for improving cerebral ischemia and its application | |
| CN114767666B (en) | Application of tamarigenin in preparing medicament for preventing or treating ischemic encephalopathy | |
| DE2352618A1 (en) | MEDICINAL PRODUCTS FOR THE TREATMENT OF PARKINSONISM | |
| CN108066373A (en) | A kind of drug and preparation method for preventing diabetes B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191018 |